Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New AG William Barr May Bring A Lighter Touch On FCA Enforcement

Executive Summary

During his January confirmation hearing, new Attorney General William Barr promised to uphold the False Claims Act. But his past statements condemning the law have some wondering how vigorous that enforcement will be.

You may also be interested in...



US High Court Won’t Hear FCA, Patent Cases

The US Supreme Court announced Monday that it won’t hear a much-watched case that could have limited the government’s ability to bring False Claims Act cases if it knew of the alleged misconduct. Two drug-world patent cases were also declined.

Device Settlements Contribute To DoJ's $2.5Bn Health-Care FCA Haul

The US Department of Justice collected $2.8bn in settlements and judgments involving violations of the False Claims Act in 2018, including $2.5bn in health-care cases. Key device industry recoveries included $33.2m from Alere, $12.5m from Angiodynamics, and $30m in two separate settlements from Covidien and its subsidiary ev3.

US DoJ Memos May Hint At Enforcement Stepdown

The US Department of Justice has ordered its attorneys to ask for the dismissal of more whistleblower cases, and to avoid basing civil enforcement actions solely on guidance documents. Both could lead to fewer enforcement actions against device manufacturers.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT124853

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel